|
Parameters
|
Group A
|
Group B
|
p value
|
|---|
|
N = 52
|
N = 40
|
|---|
|
Variables
|
|
Age at time of operation (yrs)
|
71.0 ± 8.3
|
72.1 ± 7.6
|
0.682
|
|
Body mass index (kg/m2)
|
26.9 ± 2.5
|
25.9 ± 3.1
|
0.693
|
|
ASA classification
| | |
0.829
|
|
ASA I
|
-
|
-
|
-
|
|
ASA II
|
33 (63.5 %)
|
24 (60.0 %)
| |
|
ASA III
|
19 (36.5 %)
|
16 (40.0 %)
| |
|
Hospital stay (day)
|
7.3 ± 1.6
|
6.9 ± 1.6
|
0.464
|
|
BMD of contralateral hip (T-score)
|
−4.3 ± 1.2
|
−4.2 ± 1.0
|
0.908
|
|
Femoral stem-canal ratio (%)
|
88.3 ± 5.2
|
87.6 ± 5.3
|
0.620
|
|
Follow-up (months)
|
27.1 ± 7.3
|
26.2 ± 7.4
|
0.650
|
- Group A: patients without supplementary pharmacologic treatment
- Group B: patients treated with teriparatide
- Values are shown as mean (standard deviation) or as the n (%)
- p-values for between-group comparisons were determined by the chi-squared test and Fisher’s exact test for categorical variables and Student’s t test for continuous variables
- *Statistically significant (p < 0.05)
